Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origi
- Conditions
- NECneuroendocrine carcinoma10014710
- Registration Number
- NL-OMON47011
- Lead Sponsor
- ederlands Kanker Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 39
1. Pathologically confirmed unresectable locally advanced NEC where no curative (chemoradiation) treatment options are available, and/or metastatic NECs of extrapulmonary origin as first line therapy NEC of extrapulmonary origin (WHO 2010 classification; Ki67 >20 %) including merkel cell carcinoma.
2. Measurable disease according to RECIST 1.1, on CT-scan or MRI
3. ECOG Performance status 0-2 (see Appendix 2)
4. Adequate bone marrow function as shown by: ANC*1.5 x 109/L, Platelets *100 x 109/L, Hb >6 mmol/L
5. Adequate liver function as shown by:
Total serum bilirubin *1.5 ULN
ALT and AST *2.5x ULN (*5x ULN in patients with liver metastases)
6. Adequate renal function: calculated creatinin clearance > 60ml/min. (Cockcroft-Gault formula)
7. Life expectancy of at least 3 months.
8. Male or female age * 18 years.
9. Signed informed consent.
10. Able to swallow and retain oral medication.
11. Locally advanced or metastatic lesion(s) of which a histological biopsy can safely be obtained:
a. Patients with safely accessible locally advanced or metastatic lesion(s) including bone lesions.
b. Patients not known with bleeding disorders (such as hemophilia) or bleeding complications from biopsies, dental procedures or surgeries.
c. Patients not using any anti-coagulant medication at the time of biopsy: all aspirin derivatives, NSAID*s, coumarines, platelet function inhibitors, heparins (including LMWHs) and oral factor Xa inhibitors are not allowed, unless medication can either be safely stopped or counteracted.
d. Adequate coagulation status as measured by:
i. PT < 1.5 x ULN or PT-INR < 1.5
ii. APTT < 1.5 x ULN
iii. On the day of biopsy in patients using coumarines: PT-INR < 1.5
e. Patients not known with contraindications for lidocaine (or its derivatives)
1. Previous chemotherapy for metastatic or unresectable NEC of extrapulmonary origin. (prior peri-operative chemotherapy or chemoradiation for curative intention is allowed if at least 6 months have elapsed between completion of this therapy and enrolment into the study).
2. Prior therapy with mTOR inhibitors (e.g. sirolimus, temsirolimus, deforolimus, everolimus)
3. Other malignancy within the last 5 years, except for carcinoma in situ of the cervix, or basal cell carcinoma.
4. Known intolerance or hypersensitivity to everolimus or other rapamycin analogs (e.g. sirolimus, temsirolimus) or cisplatin
5. Known impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus
6. Uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate therapy. Patients with a known history of impaired fasting glucose or diabetes mellitus (DM) may be included, however blood glucose and antidiabetic treatment must be monitored closely throughout the trial and adjusted as necessary
7. Patients who have any severe and/or uncontrolled medical conditions such as: a. unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction *6 months prior to randomization, serious uncontrolled cardiac arrhythmia. b. active or uncontrolled severe infection, c. liver disease such as cirrhosis, decompensated liver disease, and known history chronic hepatitis d. known severely impaired lung function (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on room air), e. active, bleeding diathesis;
8. Chronic treatment with corticosteroids or other immunosuppressive agents
9. Known history of HIV seropositivity
10. Pregnant or nursing (lactating) women
11. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 6 months after stopping study treatment.
12. Sexually active males, unless they use a condom during intercourse while taking study medication and for 6 months after stopping study medication.
13. History of documented congestive heart failure; angina pectoris requiring medication; evidence of transmural myocardial infarction on ECG; poorly controlled hypertension (systolic BP >180 mmHg or diastolic BP >100 mmHg); clinically significant valvular heart disease; or high risk uncontrollable arrhythmias.
14. Patients with dyspnoea at rest due to complications of advanced malignancy or other disease, or who require supportive oxygen therapy.
15. History or clinical evidence of brain metastases.
16. Any investigational drug treatment within 4 weeks of start of study treatment.
17. Radiotherapy within 4 weeks of start of study treatment (2 week interval allowed if palliative radiotherapy given to bone metastastic site peripherally and patient recovered from any acute toxicity).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary endpoint of this study will be Disease Control Rate (DCR), defined as<br /><br>the sum of Overall Response Rate (ORR) consisting of Complete (CR), Partial<br /><br>Response Rate (PR) and stable disease (SD), all according to RECIST 1.1</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints will be Time to relapse; Progression-free survival (PFS);<br /><br>Disease-free survival (DFS); Overall survival (OS); Effect on the markers<br /><br>chromogranin A (CgA) and neuron-specific enolase (NSE); Safety of everolimus in<br /><br>combination with cisplatin.<br /><br><br /><br>Exploratory endpoints will be the discovery of biomarkers (including<br /><br>circulating neuroendocrine tumour transcripts: NETTest) for treatment response;<br /><br>identification of resistance mechanisms; elucidation of driver events in NEC<br /><br>pathogenesis; identification of potential new targets for treatment. </p><br>